TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Celularity ( (CELU) ).
On December 1, 2025, Celularity Inc. received a warning letter from the FDA concerning the marketing materials for Interfyl, a human connective tissue matrix. The letter emphasized the need to limit outcome-based claims and metabolic activity descriptions in marketing to comply with regulatory standards. Despite the warning, the company’s manufacturing and shipping operations remain unaffected, and no product recalls are required. Celularity is actively engaging with the FDA to address the issues, although there is no assurance of a swift resolution. The company does not anticipate any material impact on its operational or financial expectations due to the letter.
The most recent analyst rating on (CELU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Underperform.
Celularity’s robust revenue growth is overshadowed by its lack of profitability and high financial leverage, which are significant risks. Technical indicators suggest a bearish trend with potential volatility. The negative P/E ratio and lack of dividend yield further weigh on the stock’s valuation.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. operates in the biotechnology industry, focusing on developing and manufacturing human cellular therapies and biomaterials. The company’s primary products include Interfyl, a human connective tissue matrix, with a market focus on regenerative medicine and tissue engineering.
Average Trading Volume: 131,046
Technical Sentiment Signal: Strong Sell
Current Market Cap: $55.89M
Find detailed analytics on CELU stock on TipRanks’ Stock Analysis page.